Sterling Pharma Solutions launches £11 million Material Science Centre
Sterling Pharma Solutions' new Material Science Centre.
The new centre will allow the company to improve efficiencies and reduce overall manufacturing time.
After announcing the investment last year, global contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions, has officially opened its new multi-million-pound Material Science Centre (MSC).
The three-floor MSC comprises six ISO Class 8 cleanrooms, which house four milling and micronisation suites.
The new facility also contains warehousing and workshop facilities dedicated to the milling operations, as well as a new fully equipped solid state laboratory and an analytical services laboratory and write up area.
According to the company's CEO, Kevin Cook, the centre will provide a range of specialist solid state chemistry and milling services to complement the services it already provides.
Previously, the company outsourced its solid form services to third parties. Now, in response to customer requirements, Sterling Pharma Solutions has brought them in-house.
"The centre will allow us to manage more of the product processing and as a result improve efficiencies; mitigating risk and allowing us to provide our customers with more cost-effective solutions. It will also help to reduce overall manufacturing time as we continue to develop more efficient processes, said Mr Cook.
The CDMO's solid form development team will be housed within the facility and will work to optimise existing processes across four connected areas of solid form investigation including, salt/cocrystal screening, polymorph screening, preformulation evaluation and crystallisation development.
As a result of the ongoing pandemic and visitor restrictions, Sterling will be launching the centre virtually. This will include a webinar hosted by Sterling’s experts to introduce the facility, team and services.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.